Clinical specialities

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Microfluidics #Molecular medicine #Nanomedicine / nanotechnology #Protein chemistry / Proteomics #Screening #Stem cells #System biology #Therapeutics #Translational #Translational chemistry

Engineers use ‘DNA origami’ to identify vaccine design rules

30 June 2020 Image: Glen Carrie In lab tests, virus-like DNA structures coated with viral proteins provoke a strong immune response in human B cells, by Ann Trafton, MIT News Office By folding DNA into a virus-like structure, MIT researchers have designed HIV-like particles that provoke a strong immune… Read More

#News

#Clinical specialities #Drug discovery #Regulatory #RNA

GSK receives first regulatory approval for Duvroq (daprodustat) in Japan

29 June 2020 Image: Robina Weermeijer Approval marks a significant step in GSK's global efforts to help patients with anaemia due to chronic kidney disease (CKD). GlaxoSmithKline has announced the approval of a Japanese New Drug Application (JNDA) by the Ministry of Health, Labour and Welfare for Duvroq (daprodustat) tablets,… Read More

#News #Regulatory

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Precision medicine #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

PrecisionLife identifies 68 genes associated with risk of severe COVID-19

Scientists from AI precision medicine company, PrecisionLife, have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyse the genomes of 929 patients from the UK Biobank who had a severe response to SARS-CoV-2. Prior to an effective… Read More

#Covid-19 #News

#Academic #AI / data analytics / healthtech / informatics #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Pharmacology #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Dexamethasone identified as potential for treatment of COVID-19 ten weeks ago

AI VIVO, a company combining systems pharmacology and artificial intelligence (AI) to accelerate drug discovery, has announced that its platform identified dexamethasoneas having high potential for the treatment of COVID-19 in April 2020. AI VIVO, a company combining systems pharmacology and artificial intelligence (AI) to accelerate… Read More

#Covid-19 #News

#Academic #Biomarkers #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Molecular medicine #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Mobidiag receives second tranche of financing from European Investment Bank

17 June 2020 This is the second tranche of growth capital loan signed with the European Investment Bank in May 2019. The new funds will be used for the development, manufacture and commercialisation of in vitro diagnostics for infectious diseases Mobidiag, a revenue generating, molecular diagnostics company with… Read More

#News

#AI / data analytics / healthtech / informatics #Analysis #Clinical specialities #Clinical trials #High Content Screening

AstraZeneca to present new data in treating type-2 diabetes

11 June, 2020 The British-Swedish multinational is to present new data from the landmark Phase III DAPA-HF and DECLARE-TIMI 58 trials at the upcoming 80th American Diabetes Association (ADA) Virtual Scientific Sessions, taking place June 12-26. According to AstraZeneca, the data to be presented is among 23 accepted… Read More

#News

#Assay development optimisation & technology #Biomarkers #Business #Clinical specialities #High throughput screening #Immunology #PCR #RNA #Screening

Mobidiag offers complete diagnostic solution for Covid-19 detection

The Finnish molecular diagnostics company announced it has received CE-IVD markings for its Novodiag Covid-19 and Amplidiag Covid-19 molecular diagnostic tests for the early detection of the SARS-CoV-2 virus. These tests complement Mobidiag’s already available antibody test, Anti-SARS-CoV-2 Rapid Test, that the company is distributing from its joint… Read More

#Covid-19 #News

#Business #Cell therapy #Clinical specialities #Clinical trials #Gene therapy #Oncology #Therapeutics

Oxford Biomedica and AstraZeneca sign agreement for Covid-19 vaccine

Gene and cell therapy group Oxford Biomedica has signed a one-year clinical and commercial supply agreement with AstraZeneca for the manufacture of a Covid-19 vaccine candidate. The agreement relates to the GMP manufacture of the adenovirus vector based Covid-19 vaccine candidate, AZD1222, which recently entered clinical trials at… Read More

#Covid-19 #News

#Analysis #Clinical specialities #RNA

Harmful association of glucocorticoids in interferon beta-1a treated patients

21 May, 2020 A study by Faron Pharmaceuticals Oy has shown that the desired mechanism of action of IV IFN beta-1a in the lung vasculature, the upregulation of CD73, is blocked by the administration of glucocorticoids. Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company, has announced the results… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Biomarkers #Business #Chemistry #Clinical specialities #Drug development #Drug discovery #Medicinal chemistry #RNA #System biology #Systems biology #Therapeutics

What will post-Covid-19 biotechnology look like?

Collaborative Drug Discovery (CDD), owner of the CDD Vault, a comprehensive drug discovery informatics platform for research laboratories, has asked researchers what they think biotechnology world will look like after Covid-19. A few responses are listed below. “Covid-19 may be the tipping point that shifts us from the… Read More

#Covid-19 #News

#Cell therapy #Clinical specialities #Drug development #Gene therapy #Immunology #Regulatory

Orgenesis launches cell-based vaccine platform targeting Covid-19

The global biotech company announced the launch of its new cell-based vaccine platform targeting severe acute respiratory syndrome SARS-CoV-2, as well as other viral diseases such as Zika, West Nile Virus, Yellow Fever, Dengue Fever, MERS, HCV and Cytomegalovirus infection (CMV). Orgenesis said it has been “working aggressively”… Read More

#Covid-19 #News

#Clinical specialities #PCR #RNA

Abivax’s ABX464 has potential triple action for Covid-19 treatment

The French clinical stage biotechnology company says its ABX464 is the only drug candidate with a potential triple action for Covid-19 treatment; for antiviral, anti-inflammatory and tissue repair. Abivax, a clinical stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and… Read More

#Covid-19 #News

#Business #Cell / tissue culture #Cell culture #Clinical specialities #Clinical trials #Drug development #Microbiology #RNA #Stem cells #System biology

MedPharm develops new model to support Coronavirus treatments

13 May, 2020 The UK headquartered clinical development organisation, specialised in topical and transdermal drug delivery, has expanded its testing models to support pharmaceutical development programmes targeting coronavirus treatments. MedPharm said these models allow companies to assess therapeutic effectiveness in nasal, airway (bronchial) and deep lung (alveolar) epithelia… Read More

#News

#Cell therapy #Clinical specialities #Drug development #Immunology #Immunology / Virology & Vaccines #Oncology #RNA #Stem cells

NanoPass shares Micronjet technology with global partners

The Israel based developer of nearly painless intradermal delivery solutions for vaccines and drugs said it is joining forces with leading vaccine and immunotherapy companies worldwide to share its proprietary MicronJet microneedle device. According to NanoPass, the aim is to enable the development of a safe, effective and… Read More

#Covid-19 #News

#Business #Clinical specialities #Clinical trials #High Content Screening #Immunology #Immunology / Virology & Vaccines #RNA

Agreement for research grade bioreagents for SARS-CoV-2 vaccine

GeoVax Labs, a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced on April 30 that Beijing- and Philadelphia-based Sino Biological, will be its exclusive supplier of SARS-CoV-2 (Covid-19) bioreagent research products. Under the terms of the agreement, Sino Biological will provide… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Oncology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Therapeutics

Meeting analytical challenges in a brave new world of next generation biotherapeutics

Meeting analytical challenges in a brave new world of next generation biotherapeutics By Mani Krishnan and Susan Darling Volume 21 Issue 2 - Spring 2020 The need for innovative advanced analytical tools to accelerate the development of immunotherapies and other complex biologics that may one day cure genetic diseases and… Read More

#Exclusive Content